Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Patients With Pediatric Solid Tumors (GAP)

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

December 17, 2018

Primary Completion Date

September 27, 2021

Study Completion Date

February 28, 2037

Conditions
Liver Cancer
Interventions
GENETIC

GAP T cells

"Five different dosing schedules will be evaluated. Three to six patients will be evaluated on each dosing schedule. The following dose levels will be evaluated:~DL1: 1x10\^7/m2~DL2: 3x10\^7/m2~DL3: 1x10\^8/m2~DL4: 3x10\^8/m2~DL5: 1x10\^9/m2~The doses are calculated according to the actual number of GPC3-CAR transduced T cells."

DRUG

Cytoxan

Cyclophosphamide will be given at a dose of 500 mg/m2/day for 3 days given intravenously.

DRUG

Fludara

Fludarabine will be given at a dose of 30 mg/m2/day for 3 days given intravenously.

Trial Locations (1)

77030

Texas Children's Hospital, Houston

All Listed Sponsors
collaborator

Center for Cell and Gene Therapy, Baylor College of Medicine

OTHER

collaborator

Cancer Prevention Research Institute of Texas

OTHER

collaborator

The V Foundation

OTHER

collaborator

Cookies for Kids' Cancer

OTHER

collaborator

Curing Kids' Cancer Foundation

OTHER

lead

Baylor College of Medicine

OTHER